Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Eurofins Cerep SAS is a prominent player in the global biotechnology sector, specializing in the development of innovative technologies and scientific services that support drug discovery and development. As a subsidiary of Eurofins Scientific, one of the world's leading laboratory service providers, Eurofins Cerep is committed to advancing research in pharmacology and toxicology. The company provides a comprehensive range of assays, including in vitro and in vivo pharmacological profiling, which are essential for identifying potential therapeutic compounds and evaluating their safety and efficacy. Eurofins Cerep's services are integral to pharmaceutical and biotechnology companies, aiding in the acceleration of drug development timelines and enhancing the precision of experimental results. By leveraging cutting-edge technology and a deep well of scientific expertise, Eurofins Cerep plays a critical role in the broader healthcare sector, contributing to the development of safer, more effective medical treatments. Its significant impact on research and development highlights its importance in the financial markets as a facilitator of innovation in life sciences.
€15300.00
+€0.00 (+0.00%)
Price from 5 days ago
Operating margin is thin at 8.75%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 1.3%, essentially flat. Margins also contracted 2.2pp. This is a business that needs a catalyst.
Even for strong businesses, today's 16x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
16.1x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€41M
▲ +1.3% YoY
Net Income (TTM)
€5M
▼ -33.2% YoY
Op. Margin
8.75%
▼ -2.2pp YoY
ROIC
4.83%
▼ -1.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
-€21M
Net Cash Position
Cash & Equiv.
€21M
3Y CAGR: -4.9%
Continue Research